Secondary Logo

Saved From Sepsis

Can Immunotherapy Improve Acute and Postacute Outcomes?*

Cawcutt, Kelly A., MD, MS; Kalil, Andre C., MD, MPH, FCCM

doi: 10.1097/CCM.0000000000003702
Editor's Choice

Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE

*See also p. 632.

Dr. Cawcutt received funding form Becton Dickinson/Bard, and she disclosed off-label investigational product use antiprogrammed cell death ligand-1 therapy for sepsis. Dr. Kalil has disclosed that he does not have any potential conflicts of interest.

Sepsis causes millions of deaths per year with mortality still ranging from 25% in the developed world up to 50% in developing countries (1). Sepsis-induced lymphocytopenia is common, affecting approximately 25–60% of patients with septic shock (2). Secondary immunosuppression has been in part attributed to lymphocyte cell death secondary to apoptosis (2). Apoptosis in sepsis affects multiple different cell lines including both circulatory cells such as lymphocytes and solid organ cells such as splenocytes and intestinal epithelial cells (2, 3). Lymphocyte apoptosis is reported to be two times higher than other critically ill patients and five times higher than controls (2). Of interest, neutrophils do not appear to be subject to sepsis-induced apoptosis and in fact, many patients with sepsis demonstrate neutrophilia (2). Unfortunately, the neutrophils become functionally deficient, thus still rendering them a component of the overall level of immunosuppression in sepsis.

Sepsis-induced lymphocytopenia is associated with poor outcomes among patients in the ICU, including mortality at both 28 days and 1-year survival; however, there are many other confounding factors that can also cause lymphocytopenia other than sepsis in the ICU (2, 4). Current literature suggests that the longer the persistence of the lymphocytopenia, the worse the outcome (2, 5). Sepsis-induced immunosuppressive states occur within the first few days of hospitalization and often persists beyond hospital discharge (5). Among survivors, there may be an increased risk for development of secondary infections, including healthcare-associated infections (2, 6). Further, the state of immunosuppression due to sepsis also predisposes patients to the risk of reactivation of latent viruses such as cytomegalovirus (7). The development of immunosuppression negatively impacts the prognosis of patients to survive the acute phase of sepsis resuscitation, but may also increase the risk for secondary infections both in-hospital and post-discharge, prompting hospital readmission (5, 6, 8, 9).

With increasing rates of index sepsis survivorship, there is concurrently an increased patient population at risk for hospital readmissions and secondary infections (10). Hospital readmissions after an index hospitalization for sepsis are common, with approximately 25% being readmitted within 30 days and 48% within 180 days (11, 12). Those with medical comorbidities had a higher risk of readmissions, and the majority of readmissions were secondary to infections deemed either recurrent or unresolved (11, 12). Over time, there has been a small decrease in hospital readmission for sepsis; however, this comes at the cost of increased post-sepsis Emergency Department visits (10).

Given the association with worse outcomes and potential risk of secondary infections, targeting restoration of lymphocytes is an attractive treatment strategy for sepsis. In animal models, antiprogrammed cell death ligand-1 (anti–PD-L1) antibody has been shown to inhibit lymphocyte apoptosis with overall improvement in survival (2, 13).

PD1 receptors play an integral negative role in immunoregulation and have been studied in both cancer therapy for multiple malignancies and in relation to HIV latency (13–17). Unlike cancers where PD1 up-regulation varies and thereby limits potential efficacy of therapeutic targets, PD1 is upregulated in sepsis (16). Further, among patients with sepsis due to multidrug-resistant infections, anti–PD-L1 may be associated with improvement in lymphocytopenia and increase in interferon-gamma production (3). Anti–PD-L1 has also been used for other infections, such as JC virus, hepatitis C, HIV, and mucormycosis, with promising results, but this is based on very limited evidence (3). Therapeutically, these antibodies function as immune checkpoint inhibitors to the PD-L1 and PD-L2 ligands, thereby minimizing the lymphocyte apoptosis and resultant immunosuppression (13). In sepsis models, PD1 receptors appear to be upregulated, and antibody blockade of these receptors may reduce sepsis-induced immunosuppression, therefore making this a potential therapy in patients with sepsis induced-lymphocytopenia (13).

The study Immune checkpoint inhibition in sepsis by Hotchkiss et al (18), in this issue of Critical Care Medicine, is a Phase Ib, prospective randomized double-blind placebo controlled multicenter trial of adult patients admitted to the ICU with sepsis or septic shock who had sepsis-associated immunosuppression as defined by an absolute lymphocyte count of less than or equal to 1,100 cells/μL. Patients were randomized to receive either an infusion of anti–PD-L1 (BMS-936559) at staged doses or placebo. Primary objectives were to assess the safety and tolerability of the anti–PD-L1 treatment over a total of 90 days with secondary objectives assessing the pharmacokinetics, the receptor uptake and the effect of a single dose of the drug on overall immune function via assessment of monocyte human leukocyte antigen-DR levels as a marker for immunoparalysis. Twenty-five patients were randomized and 14 completed the 90-day follow-up. The control and treatment groups were statistically different at baseline, with the treated group being older and sicker based on organ dysfunction. Adverse events recorded were not uncommon among critically ill patients and the only events reported to be believed secondary to the study treatment were an increase of amylase, lipase, and blood lactate dehydrogenase. Based on the dose given, the half-life ranged from 29 hours to 189 hours, an apparent faster elimination as compared with those with cancer. Along those receiving the single highest dose at 900 mg, the measured receptor occupancy lasted for 28 days; for the lowest dose, it lasted 8 days. There was no evidence of secondary cytokine storm secondary to therapy.

With any immune modulating therapy, the risks must be evaluated. In preventing apoptosis, there is concern for a possible cytokine storm, subsequent end-organ damage, and overall worsened survival (2, 13, 15). Although the authors cite the potential treatments adverse events including pancreatitis and pneumonitis, which are clearly of particular concern among the critically ill patients, there are other described adverse events including fatigue, varying dermatologic manifestations, hypothyroidism, hepatitis, renal failure, and neurologic toxicities (15). In fact, in the study by Hotchkiss et al (18), compared with placebo, the anti–PD-L1 treatment arm had a numerically higher number of deaths (30% vs 0%), higher grade 3–4 adverse events (35% vs 0%), higher rate of hypotension (55% vs 0%), and higher rate of respiratory disorders (25% vs 0%); even though the small sample size of the study precludes a precise interpretation, all of these safety issues had zero rate in the placebo arm. Two other limitations of this new study include the fact that a dose-effect on cytokines and human leukocyte antigen (HLA)-DR, as well as a faster immune restoration could not be detected by the use of anti–PD-L1.

The anti–PD-L1 approach has the potential to impact sepsis in two phases: 1) during the acute index sepsis episode via decrease in end-organ damage by reducing apoptosis and improving the overall immune function, assuming that a cytokine storm is not induced and 2) in the post-sepsis immunosuppression state via decrease in the subsequent risk of secondary infections while the immune system is recovering. Among major remaining questions, the critical ones are regarding the generalizability of these new study findings. At what specific stage of sepsis would immunomodulation therapy be used? Bedside cytometry following decreasing expression of HLA-DR among monocytes? Lymphocytopenia? Both? What if the patient already has pneumonitis, acute respiratory distress syndrome, hepatitis, or pancreatitis? If this only affects T cells, how would this impact the epidemiology and outcome of secondary bacterial infections? Is there any risk of an immune reconstitution syndrome and its subsequent harmful effects?

We congratulate Hotchkiss et al (18) for their important work which moves the field forward regarding the understanding of the immunotherapy effects on sepsis. Although the approach is initially appealing, the short- and long-term clinical consequences of this immunotherapy remain unknown in patients with sepsis. Larger randomized studies are needed to assess anti–PD-L1 clinical safety and efficacy, combined with a comprehensive evaluation of index sepsis and secondary infections, readmissions, and survival outcomes.

Back to Top | Article Outline


1. Machado FR, Cavalcanti AB, Bozza FA, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): An observational study. Lancet Infect Dis 2017; 17:1180–1189
2. Girardot T, Rimmelé T, Venet F, et al. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis 2017; 22:295–305
3. Thampy LK, Remy KE, Walton AH, et al. Restoration of T cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration. PLoS One 2018; 13:e0199497
4. Drewry AM, Samra N, Skrupky LP, et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 2014; 42:383–391
5. Zorio V, Venet F, Delwarde B, et al. Assessment of sepsis-induced immunosuppression at ICU discharge and 6 months after ICU discharge. Ann Intensive Care 2017; 7:80
6. van Vught LA, Klouwenberg PMK, Spitoni C, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016; 315:1469–1479
7. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37:2350–2358
8. Delano MJ, Thayer T, Gabrilovich S, et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol 2011; 186:195–202
9. Kumar V. T cells and their immunometabolism: A novel way to understanding sepsis immunopathogenesis and future therapeutics. Eur J Cell Biol 2018; 97:379–392
10. Meyer N, Harhay MO, Small DS, et al. Temporal trends in incidence, sepsis-related mortality, and hospital-based acute care after sepsis. Crit Care Med 2018; 46:354–360
11. Goodwin AJ, Rice DA, Simpson KN, et al. Frequency, cost and risk factors of readmissions among severe sepsis survivors. Crit Care Med 2015; 43:738
12. Sun A, Netzer G, Small DS, et al. Association between index hospitalization and hospital readmission in sepsis survivors. Crit Care Med 2016; 44:478–487
13. Venet F, Rimmele T, Monneret G. Management of sepsis-induced immunosuppression. Crit Care Clin 2018; 34:97–106
14. Evans VA, van der Sluis RM, Solomon A, et al. PD-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 2018; 32:1491–1497
15. Naidoo J, Page D, Li B, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375–2391
16. Teng F, Meng X, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Lett 2018; 414:166–173
17. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: Past, present, and future. J Clin Invest 2015; 125:3384–3391
18. Hotchkiss RS, Colston E, Yende S, et al. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559). Crit Care Med 2019; 47:632–642

antiprogrammed cell death ligand-1; immunomodulation; lymphocytopenia; sepsis

Copyright © by 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.